This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Drs Jones and Blumenthal comment that our study did not adequately address limitations of the lipoprotein(a) assays used for plasma levels. In particular, they state that the lipoprotein(a) assay used in 2001 through 2003 in the CGPS, an immunoturbidimetric assay from DiaSys (DiaSys Diagnostic Systems, Holzheim, Germany) measuring total mass of lipoprotein(a), is biased compared with current isoform-independent molar assays.

However, the risk estimates for myocardial infarction in our study were based on the Copenhagen City Heart Study (CCHS), in which lipoprotein(a) total mass was measured in 1991 through 1994 using a well-validated in-house turbidimetric assay using rabbit antihuman lipoprotein(a) polyclonal antibodies.¹ The polyclonal antibodies were purified by immunoadsorption against apolipoprotein B and plasminogen, ensuring no cross-reactivity with either of these components, confirmed by immunoelectrophoresis. In addition, the polyclonal antibodies were tested by Western blot targeting 12 different isoforms of lipoprotein(a), with adequate detection of all isoforms and . . . [Full Text of this Article]

Pia R. Kamstrup, MD, PhD; Børge G. Nordestgaard, MD, DMSc
brno@heh.regionh.dk
Department of Clinical Biochemistry
Copenhagen University Hospital
Herlev, Denmark

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup, Anne Tybjærg-Hansen, Rolf Steffensen, and Børge G. Nordestgaard
JAMA. 2009;301(22):2331-2339.
ABSTRACT | FULL TEXT  

RELATED LETTER

Lipoprotein(a) Measurement and Determining Risk of Myocardial Infarction
Steven R. Jones and Roger S. Blumenthal
JAMA. 2009;302(15):1645.
EXTRACT | FULL TEXT